

1. Buprenorphine and surgery. Accessed October 31, 2025. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7085354/#:~:text=The%20second%20approach%20is%20to,procedure%20with%20planned%20postoperative%20admission>
2. Cao L, Yang T, Hou Y, et al. Efficacy and safety of different preemptive analgesia measures in pain management after laparoscopic cholecystectomy: a systematic review and network meta-analysis of randomized controlled trials. *Pain Ther.* 2024;13:1471–1497. doi:10.1007/s40122-024-00647-w
3. *Drug Deliv.* 2024;31(1):2296349. doi:10.1080/10717544.2024.2296349
4. Food and Drug Administration. *FDA Orange Book*.
5. Food and Drug Administration. *JOURNAVX*. Updated September 9, 2025. Accessed October 31, 2025. <https://www.journavxhcp.com/>
6. Food and Drug Administration. *Novel Drug Approvals for 2025*.
7. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in patients with orthopaedic trauma and the risk factors for prolonged opiate use. *J Bone Joint Surg Am.* 2013;95(12):1075-1080. doi:10.2106/JBJS.L.00619
8. Keam SJ. Suzetrigine: first approval. *Drugs.* 2025;85(6):845-851. doi:10.1007/s40265-025-02178-w
9. Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. *Reg Anesth Pain Med.* 2021;46:840-859. doi:10.1136/rapm-2021-103007
10. Orhurhu V, Orhurhu M, Bhatia A, Cohen S. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. *Anesth Analg.* 2019;129(1):241-254. https://journals.lww.com/anesthesia-analgesia/abstract/2019/07000/ketamine_infusions_for_chronic_pain__a_systematic.40.aspx
11. Riddell JM. Low-dose ketamine in painful orthopaedic surgery: a systematic review and meta-analysis. *Br J Anaesth.* 2019;123(3):325-334.
12. Sleight J, Harvey M, Voss L, Denny B. Ketamine—More mechanisms of action than just NMDA blockade. *Trends Anaesth Crit Care.* 2014;4(2-3):76-81. doi:10.1016/j.tacc.2014.03.002
13. Stewart RG, Osorno T, Fujita A, et al. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor Suzetrigine. *Proc Natl Acad Sci U S A.* 2025;122(22):e2503570122. doi:10.1073/pnas.2503570122
14. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med.* 2005;6(6):432-442. doi:10.1111/j.1526-4637.2005.00072.x